Pre-made Fontolizumab biosimilar ( Whole mAb, anti-IFNG therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-219
Anti-IFNG therapeutic antibody (Pre-made Fontolizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease. A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IFNG therapeutic antibody (Pre-made Fontolizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||1t3f:BA/1t04:DC:BA|
|95-98% SI Structure||None|
|Conditions Discontinued||Autoimmune disorders;Crohn's disease;Psoriasis;Rheumatoid arthritis|